Overview
- Temple opened for pre-orders on November 1, priced at Rs 85,000, with made‑to‑order units the company says will begin shipping in early 2027.
- In early November a group of clinicians led by hepatologist Dr Cyriac Abby Philips publicly challenged Temple’s core claim that a forehead sensor can measure cerebral blood flow.
- Goyal has publicly defended the project, saying Temple has cost about $30 million to develop, about $20 million of it his personal money, and offering a 14‑day return policy as proof against fraud.
- Medical experts say the device’s optical sensors sit over superficial temporal vessels that feed the scalp and face and argue those measurements do not by themselves prove blood flow inside the brain.
- Temple has not yet published peer‑reviewed clinical validation; the company says pre‑prints are coming and expects independent studies once devices are widely used, a sequence that would materially change the public evidence base.